Category: Aastrom Biosciences Inc.

Aastrom Biosciences winds up treatment stage of Phase 2 clinical trial

March 9, 2010 by MedCity News

By Brandon Glenn

Aastrom Biosciences Inc. (NSDQ:ASTMD) finished treating patients in a Phase 2 clinical trial of its cardiac-repair stem cells.

The milestone clears the way for Aastrom to report six-month interim results of the trial later this year, according to a press release.

In the trial, Aastrom treated 40 patients suffering from dilated cardiomyopathy, a severe form of congestive heart failure in which the heart becomes weakened and enlarged and cannot pump blood efficiently.

Aastrom Biosciences back in NASDAQ's good graces

March 5, 2010 by MassDevice staff

By Brandon Glenn

ANN ARBOR, Mich. – Aastrom Biosciences (NSDQ:ASTMD), once in danger of being de-listed from the NASDAQ exchange, regained compliance with the exchange’s $1 minimum-share-price requirement.